Trial reportBJOG : an international journal of obstetrics and gynaecology2025
Aspirin, Birthweight, and Large-For-Gestational-Age Neonates: A Secondary Analysis of the ASPRE Trial.
Trial report in BJOG : an international journal of obstetrics and gynaecology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The use of echocardiography to identify acute and chronic changes in left ventricular function in hypertensive disorder of pregnancy.BMC pregnancy and childbirth · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectiveTo investigate the effects of aspirin on the distribution of birthweight and its impact on the rates of large-for-gestational-age (LGA) neonates.
designSecondary analysis of the Combined Multimarker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Preeclampsia Prevention (ASPRE) trial.
settingThirteen hospitals in England, Spain, Belgium, Greece, Italy and Israel. POPULATION: Participants of the ASPRE trial at increased risk of preterm pre-eclampsia (PE) who had a live birth.
methodsWe compared the birthweight distributions and the rates of LGA neonates between the trial groups. Analyses were stratified according to the presence of pre-existing diabetes mellitus and the development of PE, and logistic regression was used to investigate independent predictors of LGA neonates with birthweight above the 90th percentile.
main outcome measuresBirthweight distribution and rates of LGA neonates.
resultsAmong 1571 singleton, live neonates (777 from the aspirin group and 794 from the placebo group), aspirin was associated with a shift in birthweight from < 2500 to 2500-4000 g, and birthweight percentile from < 25th to 25th-75th percentiles, with no significant increase in LGA neonates (5.5% vs. 6.2%, p = 0.667). Logistic regression demonstrated a significant interaction between treatment and pre-existing diabetes (p-value 0.034), and a positive association between maternal weight and LGA neonates (adjusted odds ratio 1.040, 95% confidence interval 1.030-1.051, p < 0.001).
conclusionsAspirin use is associated with increased birthweight without increasing the rate of LGA neonates. Among women with pre-existing diabetes, aspirin may be associated with a higher rate of LGA neonates, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.